País: Canadá
Língua: inglês
Origem: Health Canada
ESTRADIOL
SANDOZ CANADA INCORPORATED
G03CA03
ESTRADIOL
50MCG
PATCH
ESTRADIOL 50MCG
TRANSDERMAL
8
Prescription
ESTROGENS
Active ingredient group (AIG) number: 0106457035; AHFS:
APPROVED
2022-12-06
_ _ _ESTRADOT® _ _Page 1 of 42_ PRODUCT MONOGRAPH Pr ESTRADOT ® 25 Transdermal Therapeutic System 25µg/24 hours of estradiol Pr ESTRADOT ® 37.5 37.5µg/24 hours of estradiol Pr ESTRADOT ® 50 50µg/24 hours of estradiol Pr ESTRADOT ® 75 75µg/24 hours of estradiol Pr ESTRADOT ® 100 100 µg/24 hours of estradiol (Estradiol-17ß) Estrogen NOVARTIS PHARMACEUTICALS CANADA INC. 385 Bouchard Blvd., Dorval, Quebec H9S 1A9 Control # 201795 Date of Revision: August 18, 2017 ESTRADOT is a registered trademark _ _ _ESTRADOT® _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................16 DOSAGE AND ADMINISTRATION ..............................................................................18 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 SPECIAL HANDLING INSTRUCTIONS .......................................................................24 STORAGE AND STABILITY ..........................................................................................24 PART II: SCIENTIFIC INFORMATION ...............................................................................26 PHARMACEUTICAL INFORMATION ..........................................................................26 CLINICAL TRIALS ............................................... Leia o documento completo